Aster DM Healthcare-QCIL merger: 14,710 beds by FY27

Deal snapshot: approvals and what changes

Aster DM Healthcare’s proposed merger with Quality Care India Ltd (QCIL) has crossed key checkpoints, including approval from the Competition Commission of India (CCI) and ‘no objection’ letters from stock exchanges. The company also received shareholder approval for the merger, with 96.68% of votes cast in favour. The merger was finalised on March 12, 2026, according to the information shared in the reports. Aster said it expects the process to be completed in the next quarter, subject to remaining regulatory and statutory approvals from the NCLT and other customary conditions. Separately, the company indicated meetings tied to the process would be held between February 27 and March 13, 2026.

The combined platform: brands, hospitals, cities, workforce

Post-integration, the merged platform is expected to be branded Aster Quality Care. It will bring together four hospital brands: Aster DM, CARE Hospitals, KIMSHEALTH and Evercare. The combined entity is described as one of India’s top three hospital chains by revenue and bed capacity in the cited reports. The merged network is expected to span 38 hospitals and 10,150+ beds across 27 cities. Another update also describes the combined operations as about 40 hospitals across 27 cities, with nearly 50,000 professionals.

Current bed base and targeted scale-up

As of September 30, 2025, the combined bed capacity of Aster DM Healthcare and QCIL stood at over 10,360 beds, with Aster operating over 5,195 beds and Quality Care India around 5,165 beds. Another figure cited for current capacity is 10,265 beds before the planned scale-up. The group has communicated an ambition to take capacity to about 14,710 to 14,715 beds over the coming years. The reports also cite a target of around 13,300 beds by FY27, and management commentary that the merger will be EPS accretive from the first year.

Capital plan: ₹4,000 crore outlay and who adds what

Founder and Chairman Azad Moopen has outlined a capital outlay of around ₹4,000 crore over the next few years to add about 4,080 beds. Of this, 2,368 beds are planned to be added by Aster DM Healthcare, with the remainder to be added by QCIL. Separately, Aster has also been reported to plan about ₹2,300 crore of investment to add 2,368 beds, through a mix of greenfield projects and selective acquisitions. The company has indicated that India remains a key growth market for the merged entity.

Where the new beds are planned: city-by-city projects

Aster’s disclosed pipeline includes two new hospitals in Bengaluru: 430 beds on Sarjapur Road and 500 beds in Yeshwanthpur. The company has also listed capacity additions of 350 beds at Aster CMI Hospital and 159 beds at Aster Whitefield. In Kerala, the 263-bed Aster Kasaragod Hospital became operational in October 2025. Work is also underway on the 454-bed greenfield Aster Capital Hospital in Thiruvananthapuram and a 100-bed expansion at Aster Medcity, Kochi. Additional projects cited include a 300-bed Women and Children’s Hospital in Hyderabad and a 75-bed expansion at Aster Ramesh, Ongole.

Recent capex already deployed: Whitefield expansion

Among recent investments, Aster has deployed ₹96 crore to expand its Whitefield Hospital in Bengaluru to 539 beds. The expansion is positioned around strengthening specialised maternity and paediatric services, as cited in the provided text. The company’s broader domestic investment programme, including Bengaluru and Thiruvananthapuram projects, is framed as part of a multi-year push to deepen its India footprint.

Expansion beyond the South: new states named

While near-term growth remains focused on southern markets such as Kerala and Karnataka, the merger is expected to broaden the company’s national footprint. Aster DM’s Deputy Managing Director Alisha Moopen has said the combined entity will expand into four additional states: Madhya Pradesh, Chhattisgarh, Tamil Nadu and Odisha. The reports also state that expansion will extend beyond Aster’s traditional strongholds.

Demerger context and fundraising considerations

The demerger of the India and GCC businesses is described as enabling sharper capital allocation, faster decision-making and clearer strategic direction. After completing the QCIL merger, Aster may also explore strategic fundraising, according to a cited report. In parallel, the group’s GCC business, backed by a Fajr Capital-led consortium and led by the Moopen family, is evaluating potential listings in the UAE and Saudi Arabia, based on the text provided.

Financial context and synergy targets referenced

One report states the consolidated entity recorded ₹7,314 crore revenue and ₹1,396 crore adjusted EBITDA in FY24. Another section notes that achieving 15-18% EBITDA synergies is seen as important to validate valuation and support ongoing expansion. These synergy expectations are presented as a key execution milestone once the integration progresses.

Key numbers table

Market impact: what investors track next

For investors, the immediate focus is on closure timelines and the remaining approvals, particularly NCLT-related processes referenced by the company. The scale-up plan is large, with capacity targeted to move from about 10,265 to ~14,710 beds, implying a multi-year capex cycle and integration work across brands and geographies. Management has framed the integration as a disciplined effort using complementary networks and clinical capabilities to scale efficiently. Execution of announced projects in Bengaluru and Kerala, alongside greenfield development in Thiruvananthapuram and additions in Hyderabad and Ongole, will be tracked against the bed-add guidance. The fundraising consideration mentioned in the report may also matter for how the group funds expansion while pursuing synergy targets.

Conclusion: timeline and next visible milestones

Aster DM Healthcare’s merger with QCIL has cleared CCI and shareholder approvals, and the combined platform is preparing for a larger national footprint under the Aster Quality Care brand. The company has outlined capacity expansion to roughly 14,710 to 14,715 beds over the coming years backed by disclosed capex and project pipelines. Next milestones include receipt of remaining regulatory and statutory approvals and the company’s stated expectation to complete the merger by the first quarter of FY2026-27, subject to conditions mentioned in the reports.